Comparing the current results to its competitors, Arcellx Inc reported Revenue decrease in the 4 quarter 2025 year on year by -89.17 %, despite the revenue increase by the most of its competitors of 8.05 %, recorded in the same quarter.
Arcellx Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical sectors, with a focus on oncology, and faces significant competition from large pharmaceutical firms, biotechnology companies, academic research institutions, governmental agencies, and both public and private research entities. Competitors include organizations developing advanced CAR-T therapies, genetically modified cell therapies, and anti-BCMA biologics. Specific competitors identified include AbbVie, Allogene, Amgen, AstraZeneca, Autolus, Bristol Myers Squibb, Cabaletta, Caribou Biosciences, CARsgen, Cartesian, Cellectis, Cellular Biomedicine Group, Celyad, Crispr, Gilead, GSK, Immix, Innovent, Johnson & Johnson, Kelonia, Kyverna, Legend, Nanjing IASO Biotherapeutics Ltd, Novartis, Pfizer, Precision BioSciences, Pregene, Regeneron, and Roche. The company also anticipates competition from entities developing immune therapies such as T-cells with CARs or TCRs reactive to tumor antigens, adapter platforms, multispecific antibodies, other immune cell-targeted therapies, natural killer cell-based therapies, in vivo CAR-T therapeutics, and allogeneic cell therapies. Market acceptance of these therapies will depend on factors including efficacy, safety, delivery methods, pricing, and reimbursement. Many competitors possess greater financial resources and research capabilities.
August 8, 2024
Arcellx Reports Promising Q2 2024 Results, Highlighting Advancements in Innovative Cell Therapies REDWOOD CITY, Calif. Arcellx, Inc. (NASDAQ: ACLX), a biotechnology leader recognized for its groundbreaking approaches to cell therapy, recently unveiled its financial results for the second quarter of 2024, marking a period of significant growth and development within the company. The firm remains dedicated to reimagining immunotherapy strategies, aiming to provide better outcomes for patients battling cancer and other challenging diseases.In a press release dated August 10, 2024, Rami Elghandour, Arcellx s Chairman and Chief Executive Officer, expressed confidence in the company s direction, stating, “We...
Vertex Pharmaceuticals Incs business model centers on the research and development of innovative therapies, primarily targeting cystic fibrosis and other serious diseases. They emphasize collaboration with organizations, strategic partnerships, and robust investment in R&D to deliver transformative treatments to patients and enhance their quality of life.
Fusion Pharmaceuticals Inc is a biopharmaceutical company that specializes in the development and commercialization of targeted alpha therapeutics for the treatment of cancer. Their business model revolves around harnessing the power of radiation to selectively kill cancer cells while sparing healthy tissues. By combining targeted alpha therapy with various cancer-targeting agents, they aim to develop innovative treatments that offer improved efficacy and reduced side effects for patients.
Bristol Myers Squibb Company operates a research and development-driven business model, focusing on the discovery and delivery of innovative medicines for various diseases. It emphasizes collaboration with academic institutions, government entities, and other pharmaceutical firms to enhance its therapeutic portfolio and improve patient outcomes.
Biogen Incs business model focuses on researching, developing, and commercializing innovative therapies primarily for neurological and neurodegenerative diseases, emphasizing advancements in precision medicine and patient care.
Sources:
Arcellx Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arcellx Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
